Summary: The role of GLP-1 receptor agonists in the treatment of type 2 diabetes has been on the rise for several years. Thanks to the favorable results of cardiovascular outcome trials, which showed a reduction in the composite primary endpoint (cardiovascular death, non-fatal myocardial infarction and stroke), the latest ADA/EASD 2022 Consensus, similarly to the current Diabetes Poland recommendations, positions them as drugs of first choice (including SGLT-2 inhibitors) in diabetic patients with overt or very high risk of cardiovascular disease, heart failure and chronic kidney disease with or without metformin. In addition to cardiovascular benefits, these drugs are very effective in lowering blood glucose levels and reducing body weight. The latter effect, confirmed in randomized, prospective studies, resulted in registration of liraglutide and semaglutide for the treatment of obesity (in doses higher than those used in the treatment of type 2 diabetes). However, due to the very favorable profile of action of these drugs and the presence of GLP-1 receptors in numerous organs and tissues of our body, this potential seems not to be fully used yet. Hence, research is being conducted on the effect of these drugs on fatty liver disease or neurodegenerative diseases. Does this exhaust the therapeutic possibilities of GLP-1 receptor agonists? We do not know, but the coming years will probably bring, at least in part, an answer to this question.